Evidence map›Paper›PMID 37501188›Full record

Observational studyOrphanet journal of rare diseases2023

Machine learning in Huntington's disease: exploring the Enroll-HD dataset for prognosis and driving capability prediction.

Jasper Ouwerkerk, Stephanie Feleus, Kasper F van der Zwaan, Yunlei Li, Marco Roos, Willeke M C van Roon-Mom, Susanne T de Bot, Katherine J Wolstencroft, Eleni Mina

Open access · goldAbstract readObservational Study
In one paragraph

Observational study in Orphanet journal of rare diseases, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.7field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Jasper OuwerkerkDepartment of Pathology and Clinical Bioinformatics, Erasmus Medical Center (EMC), Wytemaweg, 3015 CN, Rotterdam, The Netherlands.ORCID 0000-0003-2556-2125
Stephanie FeleusDepartment of Neurology, Leiden University Medical Center (LUMC), PO Box 9600, 2300 RC, Leiden, The Netherlands.ORCID 0000-0002-1160-0920
Kasper F van der ZwaanDepartment of Neurology, Leiden University Medical Center (LUMC), PO Box 9600, 2300 RC, Leiden, The Netherlands.ORCID 0000-0002-5532-5553
Yunlei LiDepartment of Pathology and Clinical Bioinformatics, Erasmus Medical Center (EMC), Wytemaweg, 3015 CN, Rotterdam, The Netherlands.ORCID 0000-0002-5697-1602
Marco RoosDepartment of Human Genetics, Leiden University Medical Center (LUMC), PO Box 9600, 2300 RC, Leiden, The Netherlands.ORCID 0000-0002-8691-772X
Willeke M C van Roon-MomDepartment of Human Genetics, Leiden University Medical Center (LUMC), PO Box 9600, 2300 RC, Leiden, The Netherlands.ORCID 0000-0002-3035-0533
Susanne T de BotDepartment of Neurology, Leiden University Medical Center (LUMC), PO Box 9600, 2300 RC, Leiden, The Netherlands.ORCID 0000-0002-3512-2468
Katherine J Wolstencroft *Leiden Institute of Advanced Computer Science (LIACS), Leiden University, Niels Bohrweg 1, 2333 CA, Leiden, The Netherlands.ORCID 0000-0002-1279-5133
Eleni Mina *Department of Human Genetics, Leiden University Medical Center (LUMC), PO Box 9600, 2300 RC, Leiden, The Netherlands. e.mina@lumc.nl.ORCID 0000-0002-8972-9206
Leiden University Medical Center · NLLeiden University · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIn biomedicine, machine learning (ML) has proven beneficial for the prognosis and diagnosis of different diseases, including cancer and neurodegenerative disorders. For rare diseases, however, the requirement for large datasets often prevents this approach. Huntington's disease (HD) is a rare neurodegenerative disorder caused by a CAG repeat expansion in the coding region of the huntingtin gene. The world's largest observational study for HD, Enroll-HD, describes over 21,000 participants. As such, Enroll-HD is amenable to ML methods. In this study, we pre-processed and imputed Enroll-HD with ML methods to maximise the inclusion of participants and variables. With this dataset we developed models to improve the prediction of the age at onset (AAO) and compared it to the well-established Langbehn formula. In addition, we used recurrent neural networks (RNNs) to demonstrate the utility of ML methods for longitudinal datasets, assessing driving capabilities by learning from previous participant assessments.

resultsSimple pre-processing imputed around 42% of missing values in Enroll-HD. Also, 167 variables were retained as a result of imputing with ML. We found that multiple ML models were able to outperform the Langbehn formula. The best ML model (light gradient boosting machine) improved the prognosis of AAO compared to the Langbehn formula by 9.2%, based on root mean squared error in the test set. In addition, our ML model provides more accurate prognosis for a wider CAG repeat range compared to the Langbehn formula. Driving capability was predicted with an accuracy of 85.2%. The resulting pre-processing workflow and code to train the ML models are available to be used for related HD predictions at: https://github.com/JasperO98/hdml/tree/main .

conclusionsOur pre-processing workflow made it possible to resolve the missing values and include most participants and variables in Enroll-HD. We show the added value of a ML approach, which improved AAO predictions and allowed for the development of an advisory model that can assist clinicians and participants in estimating future driving capability.

Indexed as

Huntington DiseaseAge of OnsetHumansMachine LearningPrognosisData pre-processingEnroll-HDHuntington’s diseaseMachine learningRecurrent neural networks

Identifiers

PMID37501188
PMCPMC10375780
OpenAlexW4385303269

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.